The Resonant Molecular Signaling (RMS) platform has been validated by our efforts as well as those of independent investigators. And TIFTD continues to explore the sub-molecular activity associated with these therapies.

RMS is a novel platform that addresses a broad spectrum of disorders via a new therapeutic approach of intra- and extra-cellular signaling.2 Based on decades of laboratory research, animal-model studies, and clinical trials, the underlying theory of RMS is that a healthy state is marked by normal signaling within and between cells while disease is caused by disruption of this norm. In addition, this theory supports a view in which:

  • disease, especially chronic disease, reflects regulatory dysfunction caused by disharmony among, between, and within complex systems;
  • disharmony is itself a manifestation of errors in signaling induced by the causative agent(s) of disease, and often occurs at the sub-molecular level; and
  • the role of RMS therapy is to restore homeodynamics by reversing or eliminating one or more inappropriate signals with the consequent re-establishment of normal biological communication.


Clinical observations such as patients responding quickly to the administration of RMS agents, dosage being independent of age or mass of the patient, and the inability to detect the agent in blood samples suggests RMS therapies represent a form of signaling that utilizes energetic pathways and that the essential mechanism of action is an energy.

As evidenced by the results of formal clinical trials, hundreds of patients have been treated with various RMS agents without significant adverse results. Additional clinical observations reveal that improvements are generally rapid and reproducible in large numbers of patients. Furthermore, laboratory and other costly tests can be reduced or avoided due to decreased toxicity, and there have been no drug interactions reported to date.

The continuing discovery and development of the various formulations comprising this platform is the mission of Beech Tree Labs, Inc.1